Email Updates

Search form

You are here

IAS 2017

July 23, 2017 to July 26, 2017

The IAS 2017 conference took place between July 23–26 in Paris. Read on for details on AVAC satellite sessions, data to watch for and a prevention roadmap

Held every two years, this year’s conference included results from several HIV prevention trials, including data from HPTN’s Phase II long-acting injectable PrEP trial as well as Janssen’s Phase II vaccine trial, important findings from PrEP clinical trials, initial evidence of impact on confronting the epidemic in Swaziland, and more!

The full conference schedule is available on the conference website, and AVAC has pulled together an HIV prevention roadmap, sortable by timing, intervention and session type (also available as a PDF). The conference organizers have also engaged with partners to create additional roadmaps, which viewable here.

Following on the Web

  • In addition to AVAC’s online commentary on Twitter and Facebook, you could follow the official conference hashtag—#IAS2017.
  • Aidsmap was the official scientific news reporter for IAS 2017 and regularly updated its IAS 2017 page. Check it out here.
  • FHI 360 was an official media sponsor and hosted a digital live coverage hub for IAS 2017 on its Crowd 360 platform.
  • IAS Live debuted this year with IAS 2017 offering access to live streaming of the opening and closing sessions as well as the plenary sessions and press conferences. All session content is available through the online programme.

Satellite Sessions

Here are details on two satellite sessions that AVAC and partners are organized:

The Next Wave of Prevention Options: An update and interactive discussion on the pipeline of injections, infusions and implants—who will use, who will deliver, who will pay
Sunday, 23 July — Maillot Room
(Download flyer)

Advocates, researchers and implementers, including Ambassador Deborah Birx, discussed HIV prevention R&D—what potential users want from the next wave of prevention options, what’s scientifically feasible, what trials might look like, the development pathways and how to work together to accelerate progress.

Future Perfect: Opportunities and Obstacles for HIV Vaccines
Sunday, 23 July — Maillot Room
(Download flyer)

This satellite featured three state-of-the-art presentations on the vaccine pipeline, including passive immunization, promising vector-platforms, and the development of envelope proteins able to elicit broadly neutralizing antibodies.